Illuminating cancer therapy via cryptic antigens

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), remains a significant challenge in oncology.
• Identifying specific tumor antigens is crucial for developing effective immunotherapies.
• Current immunotherapies often struggle with targeting solid tumors like PDAC due to antigen heterogeneity.

Purpose of the Study:

• To identify novel, immunogenic peptides restricted to pancreatic cancer.
• To explore the potential of these noncanonical HLA-peptides (ncHLAp) as targets for T cell-based therapies.
• To validate T cell receptors (TCRs) capable of recognizing PDAC-specific antigens.

Main Methods:

• Utilized a translation-informed filtering strategy to analyze genomic and proteomic data.
• Identified noncanonical HLA-I-bound peptides (ncHLAp) derived from unannotated open reading frames (ORFs).
• Validated antigen-specific T cell receptors (TCRs) targeting PDAC in preclinical models.

Main Results:

• Discovered immunogenic, cancer-restricted noncanonical HLA-I-bound peptides (ncHLAp) in pancreatic cancer.
• Uncovered cryptic antigens originating from previously unannotated ORFs.
• Validated TCRs that specifically target pancreatic ductal adenocarcinoma (PDAC) in preclinical settings.

Conclusions:

• Noncanonical HLA-peptides represent a promising source of novel cancer antigens for PDAC.
• Targeting these ncHLAp with validated TCRs offers a potential new strategy for pancreatic cancer immunotherapy.
• This study opens new avenues for developing effective immunotherapies against pancreatic cancer.